about
Osteoblasts Are the Centerpiece of the Metastatic Bone MicroenvironmentLetter: natural course of cytologically benign thyroid nodules: observation of ultrasonographic changes (endocrinol metab 2013;28:110-8, dong jun lim et Al.).Macrophage Densities Correlated with CXC Chemokine Receptor 4 Expression and Related with Poor Survival in Anaplastic Thyroid Cancer.Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth.Osteal macrophages support physiologic skeletal remodeling and anabolic actions of parathyroid hormone in bone.The role of ultrasound findings in the management of thyroid nodules with atypia or follicular lesions of undetermined significance.New Biological Markers of Bone Metabolism in Osteoporosis Treatment.The expression of tumor-associated macrophages in papillary thyroid carcinoma.Osteoblast-targeted overexpression of PPARγ inhibited bone mass gain in male mice and accelerated ovariectomy-induced bone loss in female mice.The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.Changes in Body Compositions and Basal Metabolic Rates during Treatment of Graves' Disease.Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro).Star-Shaped Intense Uptake of ¹³¹I on Whole Body Scans Can Reflect Good Therapeutic Effects of Low-Dose Radioactive Iodine Treatment of 1.1 GBq.Effects of Maternal Iodine Status during Pregnancy and Lactation on Maternal Thyroid Function and Offspring Growth and Development: A Prospective Study Protocol for the Ideal Breast Milk CohortAberrant thyroid-stimulating hormone receptor signaling increases VEGF-A and CXCL8 secretion of thyroid cancer cells, contributing to angiogenesis and tumor growthTherapeutic potential of metformin in papillary thyroid cancer in vitro and in vivoPostoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid CancerClinical factors predicting the successful discontinuation of hormone replacement therapy in patients diagnosed with primary hypothyroidism
P50
Q28077461-2927891F-EEEB-43FE-89BF-423F5ED9BA97Q37264437-EB83C232-B357-4CCD-A3B9-6C13F3FDDC33Q37316047-6E876239-94D0-4BF8-A9E3-0E397C3C58AFQ37338567-D487AF43-2342-4189-9AA0-8E189015CD28Q37543659-D71F99D9-7921-4754-A12A-5CBB00ECFA12Q38446180-5E797183-478D-4D3E-86A7-3282E931AFF2Q42386755-8045FA1E-7588-47BF-9493-EABA50B48A20Q42929951-83064325-F551-49FB-9449-7B262B7820FAQ51500318-68EADB9B-7644-4726-9679-E0015CB6A6A9Q53265307-92047580-9F67-4D0F-9816-5BAA604D4ED5Q55341739-6646B06C-543E-4140-975A-06616E4DDA34Q55412973-A271012A-DD5B-4B41-8EFC-808F7484425CQ55422207-8F67BC91-4591-4C83-BFBD-5B4CF1A3A608Q57213217-4D969BCC-92E5-415E-B251-EBF4AC874005Q57470657-4235B2CE-D539-4409-8C38-ADC28646F17CQ88031159-FA00D8B8-59ED-4464-8FF5-1273CF323AF3Q92105005-A49F056C-7107-4B98-9C02-446E24600CFCQ95943324-D92AFAD9-2F21-46E4-8B45-7711948A6A5E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sun Wook Cho
@ast
Sun Wook Cho
@en
Sun Wook Cho
@es
Sun Wook Cho
@nl
Sun Wook Cho
@sl
type
label
Sun Wook Cho
@ast
Sun Wook Cho
@en
Sun Wook Cho
@es
Sun Wook Cho
@nl
Sun Wook Cho
@sl
prefLabel
Sun Wook Cho
@ast
Sun Wook Cho
@en
Sun Wook Cho
@es
Sun Wook Cho
@nl
Sun Wook Cho
@sl
P106
P31
P496
0000-0002-7394-3830